Home page  |  Help  |  Clear
English  |  French
 Search  |  Categories  |  Titles A-Z  |  Countries  |  Compare countries  |  Index  
Full TOC
Expand Document
Expand Chapter
Preferences

close this bookThe Kenya National Drug Policy (WHO; 1994; 27 pages)
View the documentFOREWORD
View the documentABBREVIATIONS
Open this folder and view contents1. GOAL AND OBJECTIVES OF THE NATIONAL DRUG POLICY
Open this folder and view contents2. PUBLIC SECTOR DRUG SUPPLY
Open this folder and view contents3. DRUG SUPPLY BY THE PRIVATE SECTOR & NON-GOVERNMENTAL ORGANISATIONS
Open this folder and view contents4. VETERINARY DRUG SUPPLY
Open this folder and view contents5. REGULATORY CONTROL
Open this folder and view contents6. RATIONAL DRUG USE
Open this folder and view contents7. QUALITY ASSURANCE
View the document8. DRUG ABUSE
Open this folder and view contents9. IMPORTATION AND EXPORTATION OF DRUGS
close this folder10. LOCAL PRODUCTION
View the document10.1. Local Manufacture
View the document10.2. Patents
View the document10.3. Research and Development
View the document11. MANPOWER TRAINING AND DEVELOPMENT
View the document12. LEGISLATION
View the document13. MONITORING & EVALUATION
View the document14. INTERSECTORAL AND TECHNICAL COOPERATION
 

10.3. Research and Development

Pharmaceutical research and development will be encouraged to support local production.

Efforts will be made to encourage the full development of local pharmaceutical manufacturing technology, including (a) the manufacture of active ingredients (basic chemicals), (b) the manufacture of pharmaceutical excipients, and (c) improved manufacture of appropriate packaging technology.

All pharmaceutical companies operating in Kenya will be expected to contribute to pharmaceutical research and development in terms of (a) funding, by redirection of the Development Levy from the Kenya Bureau of Standards to the Pharmacy and Poisons Board, (b) manpower development by re-directing the training Levy Funds, and (c) contract Research and Development to institutions and individual scientists. Companies will be encouraged to provide research grants.

Grants given for pharmaceutical research and development will be considered for tax relief.

The priority areas for drug research and development will be developed jointly with the Ministry of Health Division of Research and Development, the Division of Pharmacy, the Department of Veterinary Services (for veterinary drugs), and other concerned parties in universities, research institutions and the private sector. A current inventory of research in the field of drugs will be established.

to previous sectionto next section

Please provide your feedback
Abbreviations
English  |  French